Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Roche Holdings Ltd ADR (RHHBY)

Roche Holdings Ltd ADR (RHHBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 314,658,112
  • Shares Outstanding, K 6,830,000
  • Annual Sales, $ 64,362 M
  • Annual Income, $ 15,247 M
  • 60-Month Beta 0.34
  • Price/Sales 4.95
  • Price/Cash Flow 14.68
  • Price/Book 8.03
Trade RHHBY with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/04/21
  • Annual Dividend & Yield 0.77 (1.57%)
  • Most Recent Dividend 0.773 on 03/18/21
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.3100 +0.57%
on 09/20/21
50.8555 -10.39%
on 08/31/21
-4.7300 (-9.40%)
since 08/20/21
3-Month
45.3100 +0.57%
on 09/20/21
51.0500 -10.73%
on 08/18/21
-1.5100 (-3.21%)
since 06/18/21
52-Week
39.7200 +14.73%
on 10/30/20
51.0500 -10.73%
on 08/18/21
-1.2700 (-2.71%)
since 09/18/20

Most Recent Stories

More News
Merck (MRK) Keytruda Gets CHMP Nod for Severe Breast Cancer

The CHMP recommends an approval of Merck's (MRK) Keytruda combo for the treatment of patients with metastatic triple-negative breast cancer.

RHHBY : 45.5700 (-1.09%)
BMY : 60.50 (-1.32%)
MRK : 71.93 (+0.35%)
LLY : 231.64 (+0.67%)
New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space

ONCY : 2.04 (+1.49%)
ONC.TO : 2.62 (-2.24%)
RHHBY : 45.5700 (-1.09%)
MRK : 71.93 (+0.35%)
BMY : 60.50 (-1.32%)
PFE : 44.20 (+0.71%)
Roche (RHHBY) Lung Cancer Drug Gets Positive CHMP Opinion

Roche (RHHBY) gets a positive CHMP opinion for Gavreto for the treatment of adult patients with RET fusion-positive advanced NSCLC.

REGN : 640.89 (-1.69%)
RHHBY : 45.5700 (-1.09%)
IRWD : 12.35 (unch)
BPMC : 105.18 (-0.77%)
Exelixis (EXEL) Gets FDA Nod for Cabometyx for Thyroid Cancer

Exelixis (EXEL) gets FDA approval for a label expansion of Cabometyx for the treatment of locally advanced or metastatic differentiated thyroid cancer.

RHHBY : 45.5700 (-1.09%)
BMY : 60.50 (-1.32%)
BAYRY : 13.2450 (-0.34%)
EXEL : 19.82 (-4.34%)
Oncology Space Rapidly Improving Cancer Therapies in Wake of Operation Warp Speed

VANCOUVER – USA News Group – Oncology data leader COTA recently released a recent survey ...

ONCY : 2.04 (+1.49%)
RHHBY : 45.5700 (-1.09%)
MRK : 71.93 (+0.35%)
BMY : 60.50 (-1.32%)
PFE : 44.20 (+0.71%)
ONC.TO : 2.62 (-2.24%)
Global Immunotherapy Drugs Market Report Analysis, Share, Revenue, Growth Rate With Forecast Overview 2029

Research Nester published a report titled which delivers detailed overview of the global immunotherapy drugs market in terms of market segmentation by type, therapy area, and by region.

MRK : 71.93 (+0.35%)
GILD : 70.96 (-0.91%)
PFE : 44.20 (+0.71%)
AZN : 58.50 (+5.29%)
BMY : 60.50 (-1.32%)
GSK : 38.85 (-0.21%)
RHHBY : 45.5700 (-1.09%)
NVS : 82.80 (-0.81%)
BAYRY : 13.2450 (-0.34%)
Bristol Myers' (BMY) Opdivo Combo for Gastric Cancer Gets CHMP Nod

Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gets positive CHMP recommendation by the EMA for treating adults with gastric cancer, among others.

REGN : 640.89 (-1.69%)
RHHBY : 45.5700 (-1.09%)
BMY : 60.50 (-1.32%)
MRK : 71.93 (+0.35%)
Biogen's (BIIB) MS Drug, Vumerity, Gets Positive CHMP Opinion

The CHMP gives a positive opinion on, and recommends granting marketing authorization to Biogen's (BIIB) Vumerity for the treatment of adults with relapsing-remitting multiple sclerosis.

REGN : 640.89 (-1.69%)
BIIB : 298.49 (-0.57%)
RHHBY : 45.5700 (-1.09%)
ALKS : 29.62 (-1.63%)
Regeneron, Lilly Get New COVID Drug Deals From Government

Regeneron (REGN) is set to supply an additional 1.4 million doses of its antibody cocktail for COVID-19, REGEN-COV while Lilly (LLY) will supply 388,000 doses of its COVID-19 antibody medicine, etesevimab...

REGN : 640.89 (-1.69%)
GSK : 38.85 (-0.21%)
RHHBY : 45.5700 (-1.09%)
LLY : 231.64 (+0.67%)
OPKO Health (OPK) Forms JV, Establishes Presence in China

OPKO Health (OPK) forms a new JV with LeaderMed to establish a presence in China through expansion of the global availability of two of the former's long-acting development products.

RHHBY : 45.5700 (-1.09%)
HSIC : 75.97 (-1.94%)
OPK : 3.79 (-3.81%)
NVST : 41.58 (-2.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 46.5333
2nd Resistance Point 46.2367
1st Resistance Point 45.9033
Last Price 45.5700
1st Support Level 45.2733
2nd Support Level 44.9767
3rd Support Level 44.6433

See More

52-Week High 51.0500
Fibonacci 61.8% 46.7219
Last Price 45.5700
Fibonacci 50% 45.3850
Fibonacci 38.2% 44.0481
52-Week Low 39.7200

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar